Literature DB >> 10743317

Implementation of influenza immunisation policy in general practice: 1997 to 1998.

L V Booth1, R Coppin, J Dunleavey, H Smith.   

Abstract

Influenza immunisation policy and practice in primary care in central southern England was surveyed in early 1998, when national guidelines advised immunisation only for people with specified 'higher risk' medical conditions or who lived in long stay facilities such as nursing or residential homes. Three hundred and one questionnaires were returned from 441 general practices (68%). Between 71% and 82% of all respondents stated that they 'always' offered influenza immunisation to adults with the specified 'higher risk' medical conditions. For children the corresponding range was 33% to 43%. We estimated that 11.5% of the combined practice population of two million had received influenza immunisation late in 1997. The age data supplied suggested that 64% of those aged over 75 years had been immunised. Seventy-four per cent of respondents said they would be willing to follow an age based policy. The total coverage figures mask suboptimal uptake in target groups, coupled with immunisation of those outside the target groups. This could be partly addressed by rewarding high coverage of target groups such as elderly people aged over 75 years and by clarifying the guidelines for immunisation of children with 'higher risk' medical conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10743317

Source DB:  PubMed          Journal:  Commun Dis Public Health        ISSN: 1462-1843


  2 in total

1.  Cross-sectional study on influenza vaccination, Germany, 1999-2000.

Authors:  Sybille Rehmet; Andrea Ammon; Günter Pfaff; Nikolaus Bocter; Lyle R Petersen
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

2.  Influenza vaccine coverage rates and perceptions on vaccination in South Korea.

Authors:  Sae Yoon Kee; Jin Soo Lee; Hee Jin Cheong; Byung Chul Chun; Joon Young Song; Won Suk Choi; Yu Mi Jo; Yoo Bin Seo; Woo Joo Kim
Journal:  J Infect       Date:  2007-06-28       Impact factor: 6.072

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.